we said "path forward" could be such as to void ptie and drrx agreement with pfizer
and that's what's happening. this goes far beyond manufacturing and, though they will try to bridge with BE studies to the original formula, at some point pfizer is likely to decide to start fresh, spend a couple more years, and not have any punishingly large royalty payments to anyone. not sure pfizer would be losing much time anyway since salvaging the current formula is likely to take years anyway.
Although ballsy , PTIE should call Pfizer's bluff by ending the deal, and be lining up Purdue Pharma as a replacement. I'm guessing Purdue would be open to many alternatives since generic competition got a recent setback..